

WEST Search History

DATE: Thursday, April 13, 2006

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L2	564/161.ccls.	378
<input type="checkbox"/>	L1	514/613.ccls.	438

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 4 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 5 JAN 13 IPC 8 searching in IFIPAT, IFIUIDB, and IFICDB
NEWS 6 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 7 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 8 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 9 JAN 30 Saved answer limit increased
NEWS 10 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA
NEWS 11 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 12 FEB 22 Status of current WO (PCT) information on STN
NEWS 13 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 14 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 15 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 16 FEB 28 MEDLINE/LMEDLINE reload improves functionality
NEWS 17 FEB 28 TOXCENTER reloaded with enhancements
NEWS 18 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral
property data
NEWS 19 MAR 01 INSPEC reloaded and enhanced
NEWS 20 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 21 MAR 08 X.25 communication option no longer available after June 2006
NEWS 22 MAR 22 EMBASE is now updated on a daily basis
NEWS 23 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 24 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC
thesaurus added in PCTFULL

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:55:24 ON 04 APR 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:55:32 ON 04 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 APR 2006 HIGHEST RN 879121-98-9

DICTIONARY FILE UPDATES: 3 APR 2006 HIGHEST RN 879121-98-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524960\Struc 1.str



```

chain nodes :
7 8 9 10 20 21 22 35 36 37 38
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 23 24 25 26 27 28 29
30 31 32 33 34
chain bonds :
3-35 6-7 7-8 8-9 8-37 9-10 9-38 10-11 17-20 18-36 20-21 21-22 21-23
26-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 13-17 14-15 14-19
15-16 17-18 18-19 23-24 23-28 24-25 25-26 26-27 27-28 29-30 29-34 30-31
31-32 32-33 33-34
exact/norm bonds :
7-8 8-9 9-10 10-11 13-17 14-19 17-18 17-20 18-19 18-36 20-21 21-22
exact bonds :
3-35 6-7 8-37 9-38 21-23 26-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 23-24
23-28 24-25 25-26 26-27 27-28 29-30 29-34 30-31 31-32 32-33 33-34

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:CLASS 36:CLASS 37:CLASS
38:CLASS


```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 13:55:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> l1 exa

SAMPLE SEARCH INITIATED 13:55:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA EXA SAM L1

=> l1 exa full

FULL SEARCH INITIATED 13:56:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 41 TO ITERATE

100.0% PROCESSED 41 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L4 1 SEA EXA FUL L1

=> file medline caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

56.54

56.75

FILE 'MEDLINE' ENTERED AT 13:56:11 ON 04 APR 2006

FILE 'CAPLUS' ENTERED AT 13:56:11 ON 04 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> l4

L5

2 L4

=> d ibib abs hitstr 1-2

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:182829 CAPLUS

DOCUMENT NUMBER: 140:217391

TITLE: Preparation of biphenyl-4-carboxylic acid
 (R)-[6-[1-[(4-fluorobenzyl)methylamino]ethylideneamino]-2(R)-hydroxyindan-1-yl]amide hemihydrate as a
 muscarinic agonist

INVENTOR(S): Bush, Julie Kay; Heath, Perry Clark

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018411	A1	20040304	WO 2003-US23260	20030812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493958	AA	20040304	CA 2003-2493958	20030812
AU 2003256791	A1	20040311	AU 2003-256791	20030812
EP 1534667	A1	20050601	EP 2003-792989	20030812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013161	A	20050614	BR 2003-13161	20030812
JP 2005536549	T2	20051202	JP 2004-530846	20030812
PRIORITY APPLN. INFO.:			US 2002-405443P	P 20020822
			WO 2003-US23260	W 20030812

GI



AB The present invention provides crystalline biphenyl-4-carboxylic acid (R)-[6-[1-[(4-fluorobenzyl)methylamino]ethylideneamino]-2(R)-hydroxyindan-1-yl]amide (I) hemihydrate, pharmaceutical compns. thereof, methods of using the same in treating disorders associated with the muscarinic receptors such as cognitive disorders, Alzheimer's disease, and schizophrenia, processes for making the same, and processes for making intermediates thereof. Thus, amination of 1,2-epoxy-6-nitroindane by aqueous ammonia and optical resolution of the resulting (1R*,2R*)-1-amino-6-nitroindan-2-ol with (S)-(+)-mandelic acid in MeOH gave (1R,2R)-1-amino-6-nitroindan-2-ol (S)-mandelate which was treated with a mixture of aqueous NaOH and toluene and underwent amidation with 4-biphenylcarbonyl chloride to give biphenyl-4-carboxylic acid [(1R,2R)-6-nitro-2-hydroxyindan-1-yl]amide (II). Hydrogenation of II over 10% Pd-C in DMF under H pressure of 50 psi for 19 h gave biphenyl-4-carboxylic acid [(1R,2R)-6-amino-2-hydroxyindan-1-yl]amide which was condensed with 1-methylthioethanone N-(4-fluorobenzyl)-N-methylimmonium iodide in the presence of 4-dimethylaminopyridine in THF at room temperature for 24 h to give, after workup and crystallization from MeCN, I acetonitrile solvate. Crystallization

of I acetonitrile solvate from aqueous MeOH gave I hemihydrate.

IT 505082-69-9P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of biphenylcarboxylic acid [[(4-fluorobenzyl)methylamino]ethylideneamino]hydroxyindanyl]amide hemihydrate as selective muscarinic agonist for treating disorders associated with muscarinic receptors)

RN 505082-69-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[(1R,2R)-6-[[1-[(4-fluorophenyl)methyl]methylamino]ethylidene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



REFERENCE COUNT:


1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:261802 CAPLUS
 DOCUMENT NUMBER: 138:287411
 TITLE: Preparation of aminoethylideneaminoindanylamides as M1 muscarinic agonists
 INVENTOR(S): Allen, Jennifer Rebecca; Hitchcock, Stephen Andrew; Liu, Bin; Turner, William Wilson, Jr.; Jamison, James Andrew
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027061	A2	20030403	WO 2002-US25969	20020909
WO 2003027061	A3	20030731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2461218	AA	20030403	CA 2002-2461218	20020909
EP 1436249	A2	20040714	EP 2002-799555	20020909
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012353	A	20040727	BR 2002-12353	20020909
CN 1556788	A	20041222	CN 2002-818550	20020909
JP 2005503433	T2	20050203	JP 2003-530652	20020909
US 2004242584	A1	20041202	US 2004-488519	20040303
NO 2004001107	A	20040315	NO 2004-1107	20040315
ZA 2004002191	A	20050511	ZA 2004-2191	20040318
PRIORITY APPLN. INFO.:			US 2001-324141P	P 20010921
			WO 2002-US25969	W 20020909
OTHER SOURCE(S):		MARPAT 138:287411		
GI				



AB Title compds. [I; Q, X, Y, Z = CR1, N; ≤2 of Q, X, Y, Z = N;

≥ 2 of Q, X, Y, Z = CH; or Y, Z = CH, QX = S; R1 = H, halo, alkoxy, alkyl; R2 = halo, alkoxy, alkyl, cyaloalkyl, cyano, CF₃, (substituted) pyridinyl, thienyl, Ph, pyrrolyl; R3 = (substituted) Ph, naphthyl, heteroaryl, benzodioxolyl; R4 = H, OH, F; R5 = H, halo, alkoxy, alkyl; R6 = H, Me; m = 1, 2; n = 1-3], were prepared for treatment of schizophrenia, Alzheimer's disease, and cognitive disorders (no data). Thus, biphenyl-4-carboxylic acid (R)-(6-amino-2(R)-hydroxyindan-1-yl)amide (preparation given), 1-methylthio-1-methyl-N-(4-fluorobenzyl)-N-methylimmonium iodide (preparation given) and 4-dimethylaminopyridine were stirred together in THF for 24 h to give biphenyl-4-carboxylic acid (R)-[6-[1-[(4-fluorobenzyl)methylamino]ethylideneamino]-2(R)-hydroxyindan-1-yl]amide.

IT 505082-69-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of aminoethylideneaminoindanylamides as muscarinic agonists)

RN 505082-69-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[(1R,2R)-6-[[1-[(4-fluorophenyl)methyl]methylamino]ethylidene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.09

67.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.50

-1.50

STN INTERNATIONAL LOGOFF AT 13:56:49 ON 04 APR 2006